REVOLUTION Medicines Inc

4. nov 2026, 23:02 UTC

Revolution Medicines reports Q3 net product revenue of $197.6 million from RASONQUE, with EPS of -$1.90 surpassing analyst expectations of -$2.38.

3. nov 2026, 21:07 UTC

Revolution Medicines, Inc. shares are advancing, benefiting from a broader market uptrend that has gained since Monday's close, despite settling lower today.

2. nov 2026, 21:09 UTC

Revolution Medicines, Inc. shares fell sharply, reaching their lowest point around midday amid notable volatility and unusually high trading volume.

30. okt 2026, 19:56 UTC

Revolution Medicines, Inc. shares are modestly higher, following four consecutive sessions of gains, despite retracing some early-session peaks.

29. okt 2026, 21:51 UTC

Revolution Medicines, Inc. is declining in after-market trading, reaching its lowest cumulative return and sitting below its 20-day moving average.

28. okt 2026, 23:16 UTC

Revolution Medicines, Inc. shares are modestly lower in after-market trading, nearly 0.75% below Wednesday's close after retracing from an early peak.

27. okt 2026, 20:07 UTC

Revolution Medicines, Inc. shares are advancing as part of a broader market rally, showing a cumulative return higher since Monday's close.

26. okt 2026, 19:51 UTC

Revolution Medicines Inc shares are declining following competitive pancreatic cancer data from Incyte Corporation, raising concerns about the company's market positioning.

23. okt 2026, 20:07 UTC

Revolution Medicines presented positive Phase 3 trial results for RASONQUE at ESMO, showing significant survival benefits over chemotherapy in metastatic pancreatic adenocarcinoma.

22. okt 2026, 23:06 UTC

Revolution Medicines Inc shares are trading modestly higher during after-market hours, fluctuating between negative and slightly positive territory since Thursday's close.

21. okt 2026, 23:31 UTC

Revolution Medicines Inc shares declined modestly in after-market trading on Wednesday, falling below its 20-day moving average and around the middle of its one-month range.

20. okt 2026, 20:02 UTC

Revolution Medicines begins patient treatment in global Phase 3 trial RASolve 308 for zoldonrasib, targeting RAS G12D mutation in metastatic non-squamous non-small cell lung cancer.

16. okt 2026, 20:02 UTC

Revolution Medicines shares declined sharply after William Blair initiated coverage with an Outperform rating and a $226 price target, citing growth potential for RAS(ON) inhibitors.

15. okt 2026, 20:07 UTC

Revolution Medicines receives a positive opinion from the European Medicines Agency for RASONQUE in metastatic pancreatic adenocarcinoma, despite shares trading lower.

14. okt 2026, 23:21 UTC

Revolution Medicines Inc shares declined significantly in after-market trading, hitting their lowest point of the day and remaining below the 20-day moving average.

13. okt 2026, 19:31 UTC

Revolution Medicines Inc shares fell sharply, retracing after a brief recovery, and are trading well below their 20-day moving average amid high market volume.

12. okt 2026, 20:06 UTC

Revolution Medicines Inc shares advanced, recovering from an early dip to achieve their highest cumulative return of the day, gaining notably since Friday's close.

9. okt 2026, 20:07 UTC

Guggenheim maintains a Buy rating on Revolution Medicines, asserting the stock's reaction to FDA review documents is overstated, as shares are modestly higher.

8. okt 2026, 23:50 UTC

Revolution Medicines Inc shares advanced in after-market trading, showing a modest increase since Thursday's close while remaining below its 20-day moving average.

7. okt 2026, 20:07 UTC

Truist Securities raised Revolution Medicines' price target to $240 from $239, maintaining a Buy rating, as shares show modest gains in today's session.

6. okt 2026, 20:02 UTC

Revolution Medicines Inc shares fell sharply today, breaking a recent trend of higher daily closes amid unusually high market volume.

5. okt 2026, 23:50 UTC

Revolution Medicines Inc saw a modest increase in after-market trading, continuing a trend of six consecutive daily gains while remaining above its 20-day moving average.

1. okt 2026, 20:07 UTC

Revolution Medicines Inc's shares are advancing as CEO Mark Goldsmith's independence strategy gains attention, positioning the company for growth in cancer treatments.

30. sept 2026, 23:30 UTC

Revolution Medicines Inc is trading modestly higher in after-market hours, supported by broader market gains and positive U.S. GDP and inflation data.

29. sept 2026, 22:10 UTC

Revolution Medicines Inc experienced a modest decline during after-market hours on Tuesday, continuing to trade within its one-month range.

28. sept 2026, 19:51 UTC

Revolution Medicines shares fell sharply despite Bank of America raising its price target to $265 and Brookline projecting $1.7 billion in revenue by 2027.

25. sept 2026, 20:02 UTC

Revolution Medicines Inc shares are advancing notably, supported by increased trading volume and positive trends in the biotechnology sector since Thursday's close.

24. sept 2026, 23:01 UTC

Revolution Medicines Inc is trading modestly lower in after-market hours, following a broader market decline and unusual volatility, remaining below its 20-day moving average.

23. sept 2026, 20:07 UTC

Revolution Medicines Inc. shares fell sharply despite receiving FDA Breakthrough Therapy Designation for RASONQUE, amid broader market declines and rising U.S. Treasury yields.

21. sept 2026, 20:02 UTC

Revolution Medicines Inc shares are trading higher as BofA Securities reaffirms a Buy rating and raises the price target to $265.